



LONDON
SCHOOL of
HYGIENE
& TROPICAL
MEDICINE



What are the long-term symptoms and complications of COVID-19: a protocol for a living systematic review

Melina Michelen¹, Louise Sigfrid², Lakshmi Manoharan², Natalie Elkheir^{2,3}, Claire Hastie⁴, Margaret O'Hara⁴, Jake C. Suett,^{4,5} Vincent Cheng,⁶ Amanda Burls¹, Carol Foote⁷ and Charitini Stavropoulou¹

1. School of Health Sciences, City, University of London, London, UK
2. ISARIC Global Support Centre, Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK
3. Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK
4. Long Covid Support
5. Queen Elizabeth Hospital Kings Lynn, UK
6. Bristol Medical School, University of Bristol, Bristol, UK
7. Freelance, Soquel, California, USA

Correspondence to C.Stavropoulou@city.ac.uk

Background

More than six months into the pandemic, our knowledge around COVID-19 continues to develop rapidly. The range of documented COVID-19 infections vary from asymptomatic to severe, but the vast majority of patients experience mild to moderate symptoms and do not require hospitalisation.[1] We have previously conducted a rapid review of the literature to identify which symptoms and signs might differentiate mild and moderate from severe COVID-19.[2] Since then, and as more data are being gathered, there is increasing evidence of a “long-tail” of COVID-19 illness, but limited information about the range and duration of symptoms experienced [3] or longer term health complications. A community app developed at King’s College London, which tracks self-reported symptoms, has shown that about one in ten will be sick for three weeks or more (<https://covid.joinzoe.com/post/covid-long-term>). Some individuals with COVID-19 have reported “fatigue, headaches and tingling nerves” that lasted months after symptom onset.[4] A recent longitudinal

cohort of 143 patients followed after hospitalisation from COVID-19 in Italy reported that 87% had at least one ongoing symptom, most (55%) reporting three or more, at 60 day follow up. Fatigue (53%), dyspnoea (43%), joint pain (27%) and chest pain (22%) were the most common ongoing symptoms,[5] but there is a variety of other symptoms and complications that have been reported including neurocognitive difficulties, muscle pains and weakness, gastrointestinal upset, rashes, metabolic disruption, thromboembolic conditions and mental health conditions.[6] A prolonged course of illness has also been reported among people with mild COVID-19 who did not require hospitalisation.[3,7,8]

The evidence to date remains fragmented as to the onset of symptoms and clinical features, how long symptoms may last, how this relates to the severity of the initial illness, and further lasting impacts to health. A better understanding of patients' projected recovery from COVID-19 is helpful to patients, healthcare professionals, policymakers and commissioners. The clinical management of persisting symptoms of COVID-19 has started to be addressed in the clinical literature[6] and NHS England has issued guidance for the multisystem needs of patients recovering from COVID-19.[9] Our findings could help identify people requiring additional rehabilitation services and, where necessary, specialist referral to establish a secondary cause of their symptoms. Our findings will also be relevant to organisations such as NHS England, which have recently launched an online COVID-19 rehab service supporting patients suffering long-term effects of the disease (<https://www.yourcovidrecovery.nhs.uk/>) or the British Society of Immunologists, which recently released a briefing note recommending research into the long-term immunological health consequences of COVID-19.[10]

The aim of this review is to evaluate the evidence on the prevalence and duration of symptoms and clinical features of post-acute COVID-19 and its long-term complications. This will inform clinical and public health management, prevention and rehabilitation policies.

Methods

To address the aim of this study we will conduct a living systematic review (LSR), which will be initially updated monthly, with update cycles under continuous review as the pace of new evidence generated develops through the pandemic. Our study methodology has been developed and strengthened through consultation with Long Covid Support (a patient support network). LSRs are used in areas where research evidence is emerging rapidly, current evidence is uncertain, and new research may influence policy or practice decisions.[11] These are all features of COVID-19 research, where much about the long-term effects of the disease are still unknown.

Inclusion/exclusion criteria

We will include studies that meet the follow criteria:

- Studies of patients with COVID-19 who have persistent mild, moderate or severe symptoms as defined by the article authors
- Studies following up with COVID-19 patients
- Peer reviewed articles published since 1st January 2020
- No restriction regarding country, setting or language

We will exclude:

- Studies that focus only on acute COVID-19
- Editorials and opinion papers

Search strategy

A search of the following databases will be conducted: Pubmed and CINAHL through the EBSCO database host for general health peer-reviewed articles and Global Health for global peer-reviewed articles through the Ovid database host. In addition, we will search the Cochrane for relevant systematic reviews and Google Scholar for grey literature including pre-prints. We will also look at the [WHO Global Research Database on COVID-19](#) and LitCOVID as two databases that bring together evidence on COVID-19 from a worldwide dataset. Finally, we will contact experts in the field and use social media to identify relevant studies.

Data will be managed using the review software Rayyan.



Key search terms:

We will search using controlled subject headings and keywords of the following concepts: Terms related to 1) COVID-19 OR COVID OR SARS-CoV-2; 2) symptoms OR clinical features OR signs OR characteristics OR sequelae OR complications; 3) long-term OR post-acute OR long-tail OR persistent OR chronic COVID OR long COVID OR post discharge OR prolonged symptoms OR long haul. The search terms have been piloted and no important studies were missed.

An example is shown below:

MEDLINE Search	
S1. COVID-19 OR OR covid OR SARS-CoV-2. ab	31,903
S2. symptom* OR "clinical features" OR signs OR characteristic* OR sequelae OR complication*.ab	188,243
S3. "long-term Covid" OR long-term N2 consequence* OR "long-term impact" OR "long-term effect" OR "post-acute" OR long-tail OR persist* OR "chronic-COVID" OR "long-COVID" OR post-discharge OR postdischarge OR "prolonged symptom" OR "long-haul" .ab	25,598
S4. S1 AND S2 AND S3	309

Screening

Initial screening of titles and abstracts as well as full text screening against the inclusion criteria will be done by two reviewers. Disagreements for inclusion will be resolved by consensus. Where disagreements cannot be resolved, a third researcher will review the papers to make the final decision.

Critical appraisal checklist

We will be using the Hoy et al checklist [12] to critically appraise the studies included in the review.

Data Extraction

The following information will be extracted from each study based on the extraction form used for our initial review [2]: study aim, country of study, setting, method, study design and population size and characteristics, types and frequency of



LONDON
SCHOOL of
HYGIENE
& TROPICAL
MEDICINE



symptoms reported, onset and duration of symptoms. Data extraction will be performed by one reviewer and checked by a second reviewer. Disagreements will be resolved through discussion and consensus.

Data analysis

We will use descriptive statistics to summarise the types of symptoms, their frequency and duration. We will perform subgroup analysis on the basis of age, sex, comorbidities and severity of the disease. The data will be presented as infographics to facilitate transcription to lay audiences.

Protocol registration

This protocol report is structured according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P) statement guidelines [13], was initially registered with OFS and PROSPERO. The protocol will be updated as we progress with the living review as and if needed.



LONDON
SCHOOL of
HYGIENE
& TROPICAL
MEDICINE



Author contributions:

Funding sources: This work was supported by the Department for International Development and Wellcome [215091/Z/18/Z] and the Bill & Melinda Gates Foundation [OPP1209135].

Guarantor: Charitini Stavropoulou is the guarantor for this study.

References:

- 1 CDC. Coronavirus Disease 2019 (COVID-19). Cent. Dis. Control Prev. 2020. <https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html> (accessed 6 Aug 2020).
- 2 Michelen M, Jones N, Stavropoulou C. In patients of COVID-19, what are the symptoms and clinical features of mild and moderate cases? <https://www.cebm.net/covid-19/in-patients-of-covid-19-what-are-the-symptoms-and-clinical-features-of-mild-and-moderate-case/> (accessed 6 Aug 2020).
- 3 Rayner C, Lokugamage AA, Molokhia M. Covid-19: Prolonged and relapsing course of illness has implications for returning workers. 2020. <https://blogs.bmj.com/bmj/2020/06/23/covid-19-prolonged-and-relapsing-course-of-illness-has-implications-for-returning-workers/> (accessed 6 Aug 2020).
- 4 Garner P. Paul Garner: Covid-19 at 14 weeks—phantom speed cameras, unknown limits, and harsh penalties - The BMJ. <https://blogs.bmj.com/bmj/2020/06/23/paul-garner-covid-19-at-14-weeks-phantom-speed-cameras-unknown-limits-and-harsh-penalties/> (accessed 6 Aug 2020).
- 5 Carfi A, Bernabei R, Landi F, *et al.* Persistent Symptoms in Patients After Acute COVID-19. *JAMA* 2020;**324**:603–5. doi:10.1001/jama.2020.12603
- 6 Greenhalgh T, Knight M, A’Court C, *et al.* Management of post-acute covid-19 in primary care. *BMJ* 2020;**370**. doi:10.1136/bmj.m3026
- 7 Tenforde MW. Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network — United States, March–June 2020. *MMWR Morb Mortal Wkly Rep* 2020;**69**. doi:10.15585/mmwr.mm6930e1
- 8 Sigfrid L, Cevik K, Jesudason E, *et al.* What is the recovery rate and risk of long-term consequences following a diagnosis of COVID-19? - A harmonised, global longitudinal observational study. *medRxiv*
- 9 NHS England and NHS Improvement. After-care needs of inpatients recovering from COVID-19. 2020. <https://www.england.nhs.uk/coronavirus/publication/after-care-needs-of-inpatients-recovering-from-covid-19/> (accessed 24 Sep 2020).
- 10 British Society for Immunology. COVID-19 immunology briefing note: What we know about long-term health consequences and priorities for research. *Immunology*.
- 11 Elliott JH, Synnot A, Turner T, *et al.* Living systematic review: 1. Introduction—the why, what, when, and how. *J Clin Epidemiol* 2017;**91**:23–30. doi:10.1016/j.jclinepi.2017.08.010
- 12 Hoy D, Brooks P, Woolf A, *et al.* Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. *J Clin Epidemiol* 2012;**65**:934–9. doi:10.1016/j.jclinepi.2011.11.014



LONDON
SCHOOL of
HYGIENE
& TROPICAL
MEDICINE



13 Moher D, Shamseer L, Clarke M, *et al.* Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev* 2015;**4**:1. doi:10.1186/2046-4053-4-1